Amneal projects $3B-$3.1B revenue in 2025 with biosimilars and CREXONT as key drivers
Q4 2024 Management View Chirag Patel, Co-CEO, highlighted Amneal's "stellar financial performance" in 2024, citing double-digit revenue and adjusted EBITDA growth, reduction of net leverage below four ...
Investing7 天
Amneal at Barclays Healthcare Conference: Growth and Innovation Insights
On Wednesday, 12 March 2025, Amneal Pharmaceuticals (NASDAQ: AMRX) participated in the Barclays 27th Annual Global Healthcare Conference 2025, where Chairman and CEO Chirag Patel outlined the ...
Business Wire15 天
Amneal’s BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA
“We have a longstanding and productive partnership with Amneal, and we are pleased to be advancing these two important products to the U.S. biosimilar market. We remain focused on our globalization ...
Business Wire8 天
Amneal to Participate at Upcoming Investor Conference
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) will present at the Barclays 27th Annual Global Healthcare Conference on March, 12, 2025. Chirag Patel, Co-Chief ...
Yahoo Finance8 天
Amneal to Participate at Upcoming Investor Conference
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a global biopharmaceutical company. We make healthy possible through the development, manufacturing, and ...